Serum triglycerides and clinical benefit in lipid-lowering trials

American Journal of Cardiology

Volumn 81, Issue 4 A, 1998, Pages

  Antero Kesaniemi Y ^a  

^a UNIVERSITY OF OULU   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; BEZAFIBRATE; ESTROGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; PRAVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

CONFERENCE PAPER; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; CORONARY RISK; ESTROGEN THERAPY; HUMAN; HYPERTRIGLYCERIDEMIA; ISCHEMIC HEART DISEASE; MORTALITY; PRIORITY JOURNAL;

ANTICHOLESTEREMIC AGENTS; ANTILIPEMIC AGENTS; BEZAFIBRATE; CHOLESTEROL, LDL; CLINICAL TRIALS; CORONARY ARTERIOSCLEROSIS; CORONARY DISEASE; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; HYPERTRIGLYCERIDEMIA; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; POSTMENOPAUSE; PRAVASTATIN; RISK FACTORS; SIMVASTATIN; TRIGLYCERIDES;

EID: 0345019842     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(98)00042-3     Document Type: Conference Paper

References (11)

1. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-1389.
2. Scandinavian Simvastatin Survival Study Group. Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S). Lancet 1995;345:1274-1275.
3. Sacks F, Pfeffer M, Moye L, Rouleau J, Rutherford J, Cole T, Brown L, Warnica W, Arnold M, Wun C-C, Davis B, Braunwald E, for the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-1009.
4. Shepherd J, Cobbe S, Ford I, Isles C, Lorimer R, Macfarlane P, McKillop J, Packard C, for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-1307.
5. Frick H, Elo O, Haapa K, Heinonen O, Heinsalmi P, Helo P, Huttunen J, Kaitaniemi P, Koskinen P, Manninen V, Mäenpää H, Mälkönen M, Mänttäri M, Norola S, Pasternack A, Pikkarainen J, Romo M, Sjöblom T, Nikkilä E. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. N Engl J Med 1987;317:1237-1245.
6. Manninen V, Elo O, Frick H, Haapa K, Heinonen O, Heinsalmi P, Helo P, Huttunen J, Kaitaniemi P, Koskinen P, Mäenpää H, Mälkönen M, Mänttäri M, Norola S, Pasternack A, Pikkarainen J, Romo M, Sjöblom T, Nikkilä E. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA 1988;260:641-651.
7. Manninen V, Tenkanen L, Koskinen P, Huttunen J, Mänttäri M, Heinonen O, Frick H. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Circulation 1992;85:37-45.
8. Carlson L, Rosenhamer G. Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand 1988;233:405-418.
9. Ericsson C-G, Hamsten A, Nilsson J, Grip L, Svane B, de Faire U. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet 1996;347:849-853.
10. The Lipid Research Clinics Coronary Primary Prevention Trial results, I: reduction in incidence of coronary heart disease. JAMA 1984;251:351-364.
11. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/ progestin regimens on heart disease risk factors in postmenopausal women. JAMA 1995;273:199-208.